Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series
Journal of Cancer Science and Clinical Therapeutics · 2026 · 10 (03)
DOI: 10.26502/jcsct.5079287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Science and Clinical Therapeutics, 2026. Verfasst von Chiara Ogliosi und 3 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ogliosi, C., Abeni, C., Peroni, A., & Zaniboni, A. (2026). Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series. Journal of Cancer Science and Clinical Therapeutics, 10(03). https://doi.org/10.26502/jcsct.5079287
Vancouver
Ogliosi C, Abeni C, Peroni A, Zaniboni A. Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series. Journal of Cancer Science and Clinical Therapeutics. 2026;10(03). doi:10.26502/jcsct.5079287
BibTeX
@article{Ogliosi2026,
author = {Ogliosi, Chiara and Abeni, Chiara and Peroni, Angelo and Zaniboni, Alberto},
title = {Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series},
journal = {Journal of Cancer Science and Clinical Therapeutics},
year = {2026},
volume = {10},
number = {03},
doi = {10.26502/jcsct.5079287}
}
EUVIMED